AGR2 and esophageal adenocarcinoma: Alternatively, in pre‐neoplastic stages such as Barrett’s esophagus, in which AGR2 was first described to inhibit p53 (Pohler et al,2004), the targeting of cytosolic AGR2 might prevent the inhibition of p53 tumor suppressor activity, thereby lowering cell transformation potential toward esophagus cancer.